T1	Participants 609 653	ouble-blind, randomized, multicenter study c
T2	Participants 854 922	included patients with mild to moderate probable Alzheimer's disease
T3	Participants 935 981	204 patients with probable Alzheimer's disease
T4	Participants 1020 1215	136 patients were eligible for the according-to-protocol analysis of efficacy, 167 subjects for the intention-to-treat analysis of efficacy, and 181 patients were included in the safety analysis.
T5	Participants 1478 1491	placebo group
